Showing 3931-3940 of 5623 results for "".
- NIH: Eye Experts Weigh In on Artificial Tears in Midst of Infectious Outbreakhttps://modernod.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/The Centers for Disease Control and Prevention (CDC) is investigating how the virulent strain of P. aeruginosa ended up in EzriCare and Delsam Pharma artificial tears. According to an
- EyeBio Announces First Asset in Pipeline of Retinal Disease Treatments and Appoints New Members to Executive Teamhttps://modernod.com/news/eyebio-announces-first-asset-in-pipeline-of-retinal-disease-treatments-and-appoints-new-members-to-executive-team/2481448/Eyebiotech Limited announced several appointments to its executive team and announced details on Restoret, the first asset in a pipeline of multi-specific agonist antibodies. EyeBio announced the following appointments to the senior leadership team: Anthony P. Adami
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Aflibercept 8 mg BLA for Treatment of Wet AMD and DME Accepted for FDA Priority Reviewhttps://modernod.com/news/aflibercept-8-mg-bla-for-treatment-of-wet-amd-and-dme-accepted-for-fda-priority-review/2481433/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. The FDA t
- CDC Expands Recall of OTC Artificial Tearshttps://modernod.com/news/cdc-expands-recall-of-otc-artificial-tears/2481430/After reports of additional infections, the Centers for Disease Control and Prevention (CDC) has expanded its recall of OTC eye drops to include Delsam Pharma’s Artificial Tears products. The call for immediate discontinuation comes a month after the agency recommended immediate discontinua
- EyeCheq adds Jai G. Parekh, MD, to its Executive Teamhttps://modernod.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/EyeCheq, the developer of a fully autonomous eye screening platform using artificial intelligence (AI), announced that Jai G. Parekh, MD, FAAO, has been named Executive Vice-President and Chief Innovation Officer. Dr. Parekh, a dual-train
- Spectrum Ophthalmics Launches New Range of Dry Eye Productshttps://modernod.com/news/spectrum-ophthalmics-launches-new-range-of-dry-eye-products/2481427/Spectrum Ophthalmics has launched a new range of dry eye products in the UK. The products include the OptiClear IPL for the treatment of dry eye disease (DED), and a 3nethra classic HD fundus camera for the diagnosis of DED. The OptiClear IPL uses light energy to rejuvenate Me